In this study, we focus on a treatment that combines AZD9496, an oral oestrogen receptor inhibitor that blocks the growth of ER- and ESR1-positive breast tumours in preclinical models, with palbociclib, a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK617–21. Here, ESR1 is linked to breast neoplasm.